These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1341242)

  • 1. Inhibition of the growth of human melanoma metastases in nude mice by melanoma-specific murine monoclonal antibody.
    Abdel-Wahab ZA; Darrow TL; Vervaert CE; Giannopoulou AA; Li W; Seigler HF
    Surg Oncol; 1992 Apr; 1(2):115-25. PubMed ID: 1341242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell binding and tumor inhibiting functions of a new antihuman melanoma murine monoclonal antibody.
    Abdel-Wahab Z; Darrow T; Vervaert CE; Crowley NJ; Seigler HF
    Mol Biother; 1991 Sep; 3(3):163-9. PubMed ID: 1768367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases.
    Eisenthal A; Lafreniere R; Lefor AT; Rosenberg SA
    Cancer Res; 1987 Jun; 47(11):2771-6. PubMed ID: 3494504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of tumor-specific cytotoxic T lymphocytes in vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2.
    Harada M; Matsuzaki G; Shinomiya Y; Kurosawa S; Ito O; Okamoto T; Takenoyama M; Sumitika H; Nishimura Y; Nomoto K
    Cancer Immunol Immunother; 1994 May; 38(5):332-8. PubMed ID: 8162615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody.
    Eisenthal A; Cameron RB; Rosenberg SA
    J Immunol; 1990 Jun; 144(11):4463-71. PubMed ID: 2111349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of pulmonary metastases using monoclonal antibody to T-cell suppressor factor and interleukin 2.
    Kim B; Warnaka P; Iverson M; Imbembo AL
    Arch Surg; 1987 Dec; 122(12):1455-9. PubMed ID: 3500692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of monoclonal antibody affinity in tumor immunotherapy evaluated in in vivo models for minimal residual disease.
    Velders MP; van Rhijn CM; Cornelissen IM; van Muijen GN; Briaire IH; Dohlsten M; Fleuren GJ; Warnaar SO; Litvinov SV
    J Immunother Emphasis Tumor Immunol; 1996 Jul; 19(4):245-56. PubMed ID: 8877719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins.
    Becker JC; Pancook JD; Gillies SD; Mendelsohn J; Reisfeld RA
    Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2702-7. PubMed ID: 8610104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy.
    Becker JC; Pancook JD; Gillies SD; Furukawa K; Reisfeld RA
    J Exp Med; 1996 May; 183(5):2361-6. PubMed ID: 8642346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.
    Vuist WM; v Buitenen F; de Rie MA; Hekman A; Rümke P; Melief CJ
    Cancer Res; 1989 Jul; 49(14):3783-8. PubMed ID: 2472198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel experimental approaches to melanoma diagnosis and therapy.
    Hearing VJ; Gersten DM; Shrayer D; Law LW
    J Dermatol; 1994 Nov; 21(11):860-9. PubMed ID: 7852647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides.
    Iliopoulos D; Ernst C; Steplewski Z; Jambrosic JA; Rodeck U; Herlyn M; Clark WH; Koprowski H; Herlyn D
    J Natl Cancer Inst; 1989 Mar; 81(6):440-4. PubMed ID: 2918552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nude mouse model to study passive humoral immunotherapy directed against B16 F10 murine melanoma.
    Shrayer D; Bogaars H; Gersten D; Hearing V; Maizel A; Wanebo H
    J Surg Oncol; 1994 Sep; 57(1):50-6. PubMed ID: 8065154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An anti-IL-2 antibody increases serum half-life and improves anti-tumor efficacy of human recombinant interleukin-2.
    Courtney LP; Phelps JL; Karavodin LM
    Immunopharmacology; 1994; 28(3):223-32. PubMed ID: 7852053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases.
    Eisenthal A; Cameron RB; Uppenkamp I; Rosenberg SA
    Cancer Res; 1988 Dec; 48(24 Pt 1):7140-5. PubMed ID: 3263900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice.
    Hardy B; Kovjazin R; Raiter A; Ganor N; Novogrodsky A
    Proc Natl Acad Sci U S A; 1997 May; 94(11):5756-60. PubMed ID: 9159146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further studies of the therapeutic effects of murine melanoma-specific monoclonal antibodies.
    Law LW; Vieira WD; Hearing VJ; Gersten DM
    Biochim Biophys Acta; 1994 Apr; 1226(1):105-9. PubMed ID: 7908833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.